17.38
0.12 (0.70%)
| Penutupan Terdahulu | 17.26 |
| Buka | 17.36 |
| Jumlah Dagangan | 1,180,820 |
| Purata Dagangan (3B) | 1,169,252 |
| Modal Pasaran | 1,241,113,984 |
| Harga / Jualan (P/S) | 8.52 |
| Harga / Buku (P/B) | 1.98 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Keuntungan | -163.17% |
| Margin Operasi (TTM) | -131.93% |
| EPS Cair (TTM) | -3.04 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 104.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 34.73% |
| Nisbah Semasa (MRQ) | 5.89 |
| Aliran Tunai Operasi (OCF TTM) | -161.55 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -84.53 M |
| Pulangan Atas Aset (ROA TTM) | -11.42% |
| Pulangan Atas Ekuiti (ROE TTM) | -34.05% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Xencor, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.63 |
|
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.24% |
| % Dimiliki oleh Institusi | 111.90% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 42.00 (Cantor Fitzgerald, 141.66%) | Beli |
| Median | 23.00 (32.34%) | |
| Rendah | 18.00 (JP Morgan, 3.57%) | Beli |
| Purata | 26.20 (50.75%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 14.68 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Truist Securities | 24 Nov 2025 | 29.00 (66.86%) | Beli | 16.74 |
| Cantor Fitzgerald | 06 Nov 2025 | 42.00 (141.66%) | Beli | 14.00 |
| 06 Oct 2025 | 40.00 (130.15%) | Beli | 11.79 | |
| JP Morgan | 06 Nov 2025 | 18.00 (3.57%) | Beli | 14.00 |
| RBC Capital | 06 Nov 2025 | 19.00 (9.32%) | Beli | 14.00 |
| 27 Oct 2025 | 18.00 (3.57%) | Beli | 14.27 | |
| Barclays | 29 Oct 2025 | 23.00 (32.34%) | Beli | 14.67 |
| 17 Sep 2025 | 6.00 (-65.48%) | Jual | 9.25 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |